Image

Health Canada has approved Bayer‘s Nexavar (sorafenib tablets) for treatment of patients with locally advanced or metastatic, progressive, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine.

Nexavar’s approval in Canada is supported by a positive outcome from the Phase III DECISION (‘stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer’) trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase III study has met the primary endpoint of progression-free survival. Sorafenib has significantly extended the progression-free survival when compared with placebo in this study.

The safety and tolerability profile of sorafenib in patients was generally consistent with the known profile of sorafenib in the trial.

The most common treatment-emergent adverse events in the sorafenib arm were hand-foot skin reaction, diarrhoea, alopecia, weight loss, fatigue, hypertension and a rash.

"The safety and tolerability profile of sorafenib in patients was generally consistent with the known profile of sorafenib in the trial."

Co-developed by Onyx Pharmaceuticals and Bayer, Nexavar is an oral anti-cancer therapy that is currently approved in more than 100 countries worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nexavar has been approved in Canada for treatment of hepatocellular carcinoma and for treating patients with advanced renal cell carcinoma who have failed or are intolerant to prior systemic therapy.

Onyx and Bayer co-promote Nexavar in the US, while Bayer has exclusive marketing rights outside of the country. The two companies share profits globally, excluding Japan.

Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of other cancers.

Image: Histopatholgical image of papillary carcinoma of the thyroid gland obtained by a total thyroidectomy. Photo: courtesy of KGH.